alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1,126–1,150 of 1,178 studies published 2024 (page 46 of 48) · 27,380 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Expo‐AD: An Innovative Alzheimer’s Disease and Related Dementias (ADRD) Research Infrastructure for Secure Data Integration and Exposome Linkage

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Alzheimer s & Dementia 2024-12-01

Access is controlled through both technical and procedural methods and overseen by an external advisory committee Results Expo‐AD is currently storing personal identifiers and neuropathology data of 10,875 brain donors acquired from 22 participating brain banks and the National Alzheimer’s Coordinating Center. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Can cerebrospinal fluid biomarkers tell us something about financial capacity in Alzheimer's disease patients? A preliminary study

✓ Peer-reviewed alzhub usefulness score 31 out of 100. Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater 2024-09-11

Although diagnostic markers in cerebrospinal fluid (CSF) have become a rapidly growing research field, they have not as yet been investigated in relation to capacities that are of interest to geriatric psychiatry and neuropsychology, such as financial capacity. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

ACCESS TO HIGH-QUALITY HOME HEALTH CARE FOR PERSONS WITH DEMENTIA

✓ Peer-reviewed alzhub usefulness score 31 out of 100. Innovation in Aging 2024-12-01

Using multiple Medicare Public Use Files (PUF), including star ratings for home health quality of patient care (QoPC), home health care CAHPS survey (HHCAHPS), county-level ADRD prevalence, and Medicare FFS enrollment, we found that the median county-level number of home health agencies was 15 (IQR 8-29), star rating was 3.4 (IQR 3.1-3.7) for QoPC and 3.8 (IQR 3.5-4.0) for HHCAHPS. 2 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Understanding perspectives and research trends in Down syndrome neuropathogenesis: A bibliometric analysis

✓ Peer-reviewed alzhub usefulness score 30 out of 100. Journal of intellectual disabilities : JOID 2024-11-13

Down syndrome (DS), characterised by compromised brain development and intellectual challenges, often manifests Alzheimer's disease (AD) -like symptoms. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The growing link between microbes, mood and mental health

✓ Peer-reviewed alzhub usefulness score 30 out of 100. Knowable Magazine 2024-01-09

Most remarkably, research by Cryan and others has shown that transplanting microbes from the guts of people with psychiatric disorders like depression to the guts of rodents can cause comparable symptoms in the animals.CREDIT: JAMES PROVOST (CC BY-ND)Neuroscientist John CryanUniversity College CorkThese effects may occur in several ways — through the vagus nerve connecting the gut to the brain, through the influence of gut bacteria on our immune systems, or by microbes synthesizing molecules that our nerve cells use to communicate. 5 key findings →

Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

The Psychosocial Analyzation of Alzheimer’s Disease and other Dementia among Black Ohioans

✓ Peer-reviewed alzhub usefulness score 30 out of 100. Alzheimer s & Dementia 2024-12-01

Black Ohioans are concerned about the rising prevalence of Alzheimer’s Disease, however social barriers that prevent equitable access to care, support and treatment is of overwhelming concern. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Amyloid Imaging Update: How the Amyloid Landscape Is Changing in Light of the Recent Food and Drug Administration Approval of Antiamyloid Therapeutics

✓ Peer-reviewed alzhub usefulness score 30 out of 100. Journal of nuclear medicine technology 2024-11-13

It has been some time since the Journal of Nuclear Medicine and Technology has published an article on best practices in amyloid imaging. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Use of Augmentative and Alternative Communication Technology to Retrain Attention and Enhance Functional Communication Following Severe Traumatic Brain Injury: A Clinical Case Report

✓ Peer-reviewed alzhub usefulness score 29 out of 100. Perspectives of the ASHA Special Interest Groups 2024-11-11

Through systematic instruction and retraining visual and sustained attention, the patient was able to engage meaningfully with a high-tech device to increase functional personal choice when supported by a partner. 2 key findings →

Design: case report Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Effect of a Financial Incentive Scheme for Medication Review on Polypharmacy in Elderly Inpatients With Dementia: A Retrospective Before-and-After Study

✓ Peer-reviewed alzhub usefulness score 28 out of 100. Journal of patient safety 2024-10-18

Polypharmacy is an important healthcare issue, especially in elderly patients with dementia. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Acquired Risk Factors that Influence Risk for Dementia and Possibly Alzheimer Disease

✓ Peer-reviewed alzhub usefulness score 27 out of 100. South Dakota medicine : the journal of the South Dakota State Medical Association 2024-02-01

Various medicinal agents aimed at improving Alzheimer disease (AD) include cholinesterase inhibitors, memantine, aducanumab, and antioxidants. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed